Radiation therapy remains an imperative treatment modality for numerous malignancies. Enduring significant technical achievements both on the levels of treatment planning and radiation delivery have led to improvements in local control of tumor growth and reduction in healthy tissue toxicity. Nevertheless, resistance mechanisms, which presumably also involve activation of DNA damage response signaling pathways that eventually may account for loco-regional relapse and consequent tumor progression, still remain a critical problem. Accumulating data suggest that signaling via growth factor receptor tyrosine kinases, which are aberrantly expressed in many tumors, may interfere with the cytotoxic impact of ionizing radiation via the direct activation of the DNA damage response, leading eventually to so-called tumor radioresistance. The aim of this review is to overview the current known data that support a molecular crosstalk between the hepatocyte growth factor receptor tyrosine kinase MET and the DNA damage response. Apart of extending well established concepts over MET biology beyond its function as a growth factor receptor, these observations directly relate to the role of its aberrant activity in resistance to DNA damaging agents, such as ionizing radiation, which are routinely used in cancer therapy and advocate tumor sensitization towards DNA damaging agents in combination with MET targeting.
References
[1]
Cooper, C.S.; Park, M.; Blair, D.G.; Tainsky, M.A.; Huebner, K.; Croce, C.M.; vande Woude, G.F. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984, 311, 29–33, doi:10.1038/311029a0.
[2]
Bottaro, D.P.; Rubin, J.S.; Faletto, D.L.; Chan, A.M.; Kmiecik, T.E.; vande Woude, G.F.; Aaronson, S.A. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991, 251, 802–804.
[3]
Iyer, A.; Kmiecik, T.E.; Park, M.; Daar, I.; Blair, D.; Dunn, K.J.; Sutrave, P.; Ihle, J.N.; Bodescot, M.; vande Woude, G.F. Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene. Cell Growth Differ. 1990, 1, 87–95.
[4]
Zhang, Y.W.; Su, Y.; Volpert, O.V.; vande Woude, G.F. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc. Natl. Acad. Sci. USA 2003, 100, 12718–12723, doi:10.1073/pnas.2135113100.
[5]
Knowles, L.M.; Stabile, L.P.; Egloff, A.M.; Rothstein, M.E.; Thomas, S.M.; Gubish, C.T.; Lerner, E.C.; Seethala, R.R.; Suzuki, S.; Quesnelle, K.M.; et al. HGF and c-MET participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin. Cancer Res. 2009, 15, 3740–3750.
[6]
Lengyel, E.; Prechtel, D.; Resau, J.H.; Gauger, K.; Welk, A.; Lindemann, K.; Salanti, G.; Richter, T.; Knudsen, B.; vande Woude, G.F.; et al. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of HER2/NEU. Int. J. Cancer 2005, 113, 678–682, doi:10.1002/ijc.20598.
[7]
Tokunou, M.; Niki, T.; Eguchi, K.; Iba, S.; Tsuda, H.; Yamada, T.; Matsuno, Y.; Kondo, H.; Saitoh, Y.; Imamura, H.; et al. c-MET expression in myofibroblasts: Role in autocrine activation and prognostic significance in lung adenocarcinoma. Am. J. Pathol. 2001, 158, 1451–1463, doi:10.1016/S0002-9440(10)64096-5.
[8]
Ramirez, R.; Hsu, D.; Patel, A.; Fenton, C.; Dinauer, C.; Tuttle, R.M.; Francis, G.L. Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma. Clin. Endocrinol. (Oxf.) 2000, 53, 635–644, doi:10.1046/j.1365-2265.2000.01124.x.
[9]
Koochekpour, S.; Jeffers, M.; Rulong, S.; Taylor, G.; Klineberg, E.; Hudson, E.A.; Resau, J.H.; vande Woude, G.F. MET and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res. 1997, 57, 5391–5398.
[10]
Di Renzo, M.F.; Poulsom, R.; Olivero, M.; Comoglio, P.M.; Lemoine, N.R. Expression of the MET/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res. 1995, 55, 1129–1138.
[11]
Liu, C.; Park, M.; Tsao, M.S. Overexpression of c-MET proto-oncogene but not epidermal growth factor receptor or c-ERBB-2 in primary human colorectal carcinomas. Oncogene 1992, 7, 181–185.
[12]
Kelsen, D.P.; Minsky, B.; Smith, M.; Beitler, J.; Niedzwiecki, D.; Chapman, D.; Bains, M.; Burt, M.; Heelan, R.; Hilaris, B. Preoperative therapy for esophageal cancer: A randomized comparison of chemotherapy versus radiation therapy. J. Clin. Oncol. 1990, 8, 1352–1361.
[13]
Pennacchietti, S.; Michieli, P.; Galluzzo, M.; Mazzone, M.; Giordano, S.; Comoglio, P.M. Hypoxia promotes invasive growth by transcriptional activation of the MET protooncogene. Cancer Cell 2003, 3, 347–361, doi:10.1016/S1535-6108(03)00085-0.
[14]
Cappuzzo, F.; Marchetti, A.; Skokan, M.; Rossi, E.; Gajapathy, S.; Felicioni, L.; del Grammastro, M.; Sciarrotta, M.G.; Buttitta, F.; Incarbone, M.; et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J. Clin. Oncol. 2009, 27, 1667–1674, doi:10.1200/JCO.2008.19.1635.
[15]
Beau-Faller, M.; Ruppert, A.M.; Voegeli, A.C.; Neuville, A.; Meyer, N.; Guerin, E.; Legrain, M.; Mennecier, B.; Wihlm, J.M.; Massard, G.; et al. MET gene copy number in non-small cell lung cancer: Molecular analysis in a targeted tyrosine kinase inhibitor naive cohort. J. Thorac. Oncol. 2008, 3, 331–339, doi:10.1097/JTO.0b013e318168d9d4.
[16]
Miller, C.T.; Lin, L.; Casper, A.M.; Lim, J.; Thomas, D.G.; Orringer, M.B.; Chang, A.C.; Chambers, A.F.; Giordano, T.J.; Glover, T.W.; et al. Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 2006, 25, 409–418.
[17]
Schmidt, L.; Duh, F.M.; Chen, F.; Kishida, T.; Glenn, G.; Choyke, P.; Scherer, S.W.; Zhuang, Z.; Lubensky, I.; Dean, M.; et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 1997, 16, 68–73, doi:10.1038/ng0597-68.
[18]
Comoglio, P.M.; Boccaccio, C. Scatter factors and invasive growth. Semin. Cancer Biol. 2001, 11, 153–165, doi:10.1006/scbi.2000.0366.
Gentile, A.; Trusolino, L.; Comoglio, P.M. The MET tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev. 2008, 27, 85–94, doi:10.1007/s10555-007-9107-6.
[21]
Ma, P.C.; Tretiakova, M.S.; MacKinnon, A.C.; Ramnath, N.; Johnson, C.; Dietrich, S.; Seiwert, T.; Christensen, J.G.; Jagadeeswaran, R.; Krausz, T.; et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosom. Cancer 2008, 47, 1025–1037, doi:10.1002/gcc.20604.
[22]
Ferracini, R.; di Renzo, M.F.; Scotlandi, K.; Baldini, N.; Olivero, M.; Lollini, P.; Cremona, O.; Campanacci, M.; Comoglio, P.M. The MET/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 1995, 10, 739–749.
[23]
Rong, S.; Segal, S.; Anver, M.; Resau, J.H.; vande Woude, G.F. Invasiveness and metastasis of NIH 3T3 cells induced by MET-hepatocyte growth factor/scatter factor autocrine stimulation. Proc. Natl. Acad. Sci. USA 1994, 91, 4731–4735, doi:10.1073/pnas.91.11.4731.
[24]
Gherardi, E.; Birchmeier, W.; Birchmeier, C.; vande Woude, G. Targeting MET in cancer: Rationale and progress. Nat. Rev. Cancer 2012, 12, 89–103, doi:10.1038/nrc3205.
Moding, E.J.; Kastan, M.B.; Kirsch, D.G. Strategies for optimizing the response of cancer and normal tissues to radiation. Nat. Rev. Drug Discov. 2013, 12, 526–542, doi:10.1038/nrd4003.
[27]
Meyer, J.L.; Leibel, S.; Roach, M.; Vijayakumar, S. New technologies for the radiotherapy of prostate cancer. A discussion of clinical treatment programs. Front. Radiat. Ther. Oncol. 2007, 40, 315–337.
[28]
Curtin, N.J. DNA repair dysregulation from cancer driver to therapeutic target. Nat. Rev. Cancer 2012, 12, 801–817, doi:10.1038/nrc3399.
[29]
Baumann, M. Keynote comment: Radiotherapy in the age of molecular oncology. Lancet Oncol. 2006, 7, 786–787, doi:10.1016/S1470-2045(06)70871-3.
[30]
Rodrigues, G.; Sanatani, M. Age and comorbidity considerations related to radiotherapy and chemotherapy administration. Semin. Radiat. Oncol. 2012, 22, 277–283.
[31]
Plataniotis, G.A.; Dale, R.G. Radio-chemotherapy for bladder cancer: Contribution of chemotherapy on local control. World J. Radiol. 2013, 5, 267–274, doi:10.4329/wjr.v5.i8.267.
[32]
Zaorsky, N.G.; Trabulsi, E.J.; Lin, J.; Den, R.B. Multimodality therapy for patients with high-risk prostate cancer: Current status and future directions. Semin. Oncol. 2013, 40, 308–321, doi:10.1053/j.seminoncol.2013.04.006.
[33]
Zhivotovsky, B.; Joseph, B.; Orrenius, S. Tumor radiosensitivity and apoptosis. Exp. Cell Res. 1999, 248, 10–17, doi:10.1006/excr.1999.4452.
[34]
Hockel, M.; Schlenger, K.; Mitze, M.; Schaffer, U.; Vaupel, P. Hypoxia and radiation response in human tumors. Semin. Radiat. Oncol. 1996, 6, 3–9, doi:10.1016/S1053-4296(96)80031-2.
[35]
Baumann, M.; Krause, M.; Dikomey, E.; Dittmann, K.; Dorr, W.; Kasten-Pisula, U.; Rodemann, H.P. EGFR-targeted anti-cancer drugs in radiotherapy: Preclinical evaluation of mechanisms. Radiother. Oncol. 2007, 83, 238–248, doi:10.1016/j.radonc.2007.04.006.
[36]
Abraham, R.T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 2001, 15, 2177–2196, doi:10.1101/gad.914401.
[37]
Abraham, R.T. PI 3-kinase related kinases: ‘Big’ players in stress-induced signaling pathways. DNA Repair (Amst.) 2004, 3, 883–887, doi:10.1016/j.dnarep.2004.04.002.
[38]
Shiloh, Y. ATM and ATR: Networking cellular responses to DNA damage. Curr. Opin. Genet. Dev. 2001, 11, 71–77, doi:10.1016/S0959-437X(00)00159-3.
[39]
Bartek, J.; Bartkova, J.; Lukas, J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 2007, 26, 7773–7779.
[40]
Bartkova, J.; Horejsi, Z.; Koed, K.; Kramer, A.; Tort, F.; Zieger, K.; Guldberg, P.; Sehested, M.; Nesland, J.M.; Lukas, C.; et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434, 864–870, doi:10.1038/nature03482.
Lavin, M.F.; Kozlov, S. ATM activation and DNA damage response. Cell Cycle 2007, 6, 931–942, doi:10.4161/cc.6.8.4180.
[43]
Zou, L.; Elledge, S.J. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 2003, 300, 1542–1548, doi:10.1126/science.1083430.
[44]
Harper, J.W.; Elledge, S.J. The DNA damage response: Ten years after. Mol. Cell 2007, 28, 739–745, doi:10.1016/j.molcel.2007.11.015.
[45]
Andreassen, P.R.; Ho, G.P.; D’Andrea, A.D. DNA damage responses and their many interactions with the replication fork. Carcinogenesis 2006, 27, 883–892, doi:10.1093/carcin/bgi319.
[46]
Zhou, B.B.; Bartek, J. Targeting the checkpoint kinases: Chemosensitization versus chemoprotection. Nat. Rev. Cancer 2004, 4, 216–225, doi:10.1038/nrc1296.
[47]
Zhou, B.B.; Elledge, S.J. The DNA damage response: Putting checkpoints in perspective. Nature 2000, 408, 433–439, doi:10.1038/35044005.
[48]
Jazayeri, A.; Falck, J.; Lukas, C.; Bartek, J.; Smith, G.C.; Lukas, J.; Jackson, S.P. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat. Cell Biol. 2006, 8, 37–45, doi:10.1038/ncb1337.
[49]
Branzei, D.; Foiani, M. Regulation of DNA repair throughout the cell cycle. Nat. Rev. Mol. Cell Biol. 2008, 9, 297–308, doi:10.1038/nrm2351.
[50]
Karlsson-Rosenthal, C.; Millar, J.B. CDC25: Mechanisms of checkpoint inhibition and recovery. Trends Cell Biol. 2006, 16, 285–292, doi:10.1016/j.tcb.2006.04.002.
[51]
Antoni, L.; Sodha, N.; Collins, I.; Garrett, M.D. CHK2 kinase: Cancer susceptibility and cancer therapy—Two sides of the same coin? Nat. Rev. Cancer 2007, 7, 925–936, doi:10.1038/nrc2251.
[52]
Zaugg, K.; Su, Y.W.; Reilly, P.T.; Moolani, Y.; Cheung, C.C.; Hakem, R.; Hirao, A.; Liu, Q.; Elledge, S.J.; Mak, T.W. Cross-talk between Chk1 and Chk2 in double-mutant thymocytes. Proc. Natl. Acad. Sci. USA 2007, 104, 3805–3810, doi:10.1073/pnas.0611584104.
[53]
Stiff, T.; Walker, S.A.; Cerosaletti, K.; Goodarzi, A.A.; Petermann, E.; Concannon, P.; O’Driscoll, M.; Jeggo, P.A. ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling. EMBO J. 2006, 25, 5775–5782, doi:10.1038/sj.emboj.7601446.
[54]
Ashwell, S.; Zabludoff, S. DNA damage detection and repair pathways—Recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin. Cancer Res. 2008, 14, 4032–4037, doi:10.1158/1078-0432.CCR-07-5138.
[55]
Ashwell, S.; Janetka, J.W.; Zabludoff, S. Keeping checkpoint kinases in line: New selective inhibitors in clinical trials. Expert Opin. Investig. Drugs 2008, 17, 1331–1340, doi:10.1517/13543784.17.9.1331.
[56]
Damia, G.; D’Incalci, M. Targeting DNA repair as a promising approach in cancer therapy. Eur. J. Cancer 2007, 43, 1791–1801, doi:10.1016/j.ejca.2007.05.003.
[57]
Pollard, J.M.; Gatti, R.A. Clinical radiation sensitivity with DNA repair disorders: An overview. Int. J. Radiat. Oncol. Biol. Phys. 2009, 74, 1323–1331, doi:10.1016/j.ijrobp.2009.02.057.
[58]
Schmidt-Ullrich, R.K.; Mikkelsen, R.B.; Dent, P.; Todd, D.G.; Valerie, K.; Kavanagh, B.D.; Contessa, J.N.; Rorrer, W.K.; Chen, P.B. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 1997, 15, 1191–1197.
[59]
Schmidt-Ullrich, R.K.; Valerie, K.; Fogleman, P.B.; Walters, J. Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. Radiat. Res. 1996, 145, 81–85, doi:10.2307/3579199.
[60]
Contessa, J.N.; Reardon, D.B.; Todd, D.; Dent, P.; Mikkelsen, R.B.; Valerie, K.; Bowers, G.D.; Schmidt-Ullrich, R.K. The inducible expression of dominant-negative epidermal growth factor receptor-CD533 results in radiosensitization of human mammary carcinoma cells. Clin. Cancer Res. 1999, 5, 405–411.
[61]
Dent, P.; Reardon, D.B.; Park, J.S.; Bowers, G.; Logsdon, C.; Valerie, K.; Schmidt-Ullrich, R. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol. Biol. Cell 1999, 10, 2493–2506, doi:10.1091/mbc.10.8.2493.
[62]
Lammering, G.; Hewit, T.H.; Hawkins, W.T.; Contessa, J.N.; Reardon, D.B.; Lin, P.S.; Valerie, K.; Dent, P.; Mikkelsen, R.B.; Schmidt-Ullrich, R.K. Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J. Natl. Cancer Inst. 2001, 93, 921–929, doi:10.1093/jnci/93.12.921.
[63]
Bandyopadhyay, D.; Mandal, M.; Adam, L.; Mendelsohn, J.; Kumar, R. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J. Biol. Chem. 1998, 273, 1568–1573, doi:10.1074/jbc.273.3.1568.
[64]
Huang, S.M.; Harari, P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. 2000, 6, 2166–2174.
[65]
Yacoub, A.; McKinstry, R.; Hinman, D.; Chung, T.; Dent, P.; Hagan, M.P. Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat. Res. 2003, 159, 439–452, doi:10.1667/0033-7587(2003)159[0439:EGFAIR]2.0.CO;2.
Dittmann, K.; Mayer, C.; Fehrenbacher, B.; Schaller, M.; Raju, U.; Milas, L.; Chen, D.J.; Kehlbach, R.; Rodemann, H.P. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J. Biol. Chem. 2005, 280, 31182–31189, doi:10.1074/jbc.M506591200.
[68]
Li, L.; Wang, H.; Yang, E.S.; Arteaga, C.L.; Xia, F. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res. 2008, 68, 9141–9146, doi:10.1158/0008-5472.CAN-08-1127.
[69]
Bonner, J.A.; Harari, P.M.; Giralt, J.; Azarnia, N.; Shin, D.M.; Cohen, R.B.; Jones, C.U.; Sur, R.; Raben, D.; Jassem, J.; et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2006, 354, 567–578, doi:10.1056/NEJMoa053422.
[70]
Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129–2139, doi:10.1056/NEJMoa040938.
[71]
Bell, D.W.; Lynch, T.J.; Haserlat, S.M.; Harris, P.L.; Okimoto, R.A.; Brannigan, B.W.; Sgroi, D.C.; Muir, B.; Riemenschneider, M.J.; Iacona, R.B.; et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. 2005, 23, 8081–8092, doi:10.1200/JCO.2005.02.7078.
[72]
Shigematsu, H.; Gazdar, A.F. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int. J. Cancer 2006, 118, 257–262, doi:10.1002/ijc.21496.
[73]
Amann, J.; Kalyankrishna, S.; Massion, P.P.; Ohm, J.E.; Girard, L.; Shigematsu, H.; Peyton, M.; Juroske, D.; Huang, Y.; Stuart Salmon, J.; et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 2005, 65, 226–235.
[74]
Arao, T.; Fukumoto, H.; Takeda, M.; Tamura, T.; Saijo, N.; Nishio, K. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res. 2004, 64, 9101–9104, doi:10.1158/0008-5472.CAN-04-2360.
[75]
Engelman, J.A.; Janne, P.A.; Mermel, C.; Pearlberg, J.; Mukohara, T.; Fleet, C.; Cichowski, K.; Johnson, B.E.; Cantley, L.C. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl. Acad. Sci. USA 2005, 102, 3788–3793, doi:10.1073/pnas.0409773102.
[76]
Sordella, R.; Bell, D.W.; Haber, D.A.; Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305, 1163–1167, doi:10.1126/science.1101637.
[77]
Das, A.K.; Sato, M.; Story, M.D.; Peyton, M.; Graves, R.; Redpath, S.; Girard, L.; Gazdar, A.F.; Shay, J.W.; Minna, J.D.; et al. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res. 2006, 66, 9601–9608, doi:10.1158/0008-5472.CAN-06-2627.
[78]
Das, A.K.; Chen, B.P.; Story, M.D.; Sato, M.; Minna, J.D.; Chen, D.J.; Nirodi, C.S. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res. 2007, 67, 5267–5274, doi:10.1158/0008-5472.CAN-07-0242.
[79]
Miller, B.S.; Yee, D. Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res. 2005, 65, 10123–10127, doi:10.1158/0008-5472.CAN-05-2752.
[80]
Larsson, O.; Girnita, A.; Girnita, L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br. J. Cancer 2005, 92, 2097–2101, doi:10.1038/sj.bjc.6602627.
[81]
Pollak, M.N.; Schernhammer, E.S.; Hankinson, S.E. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 2004, 4, 505–518, doi:10.1038/nrc1387.
[82]
Tao, Y.; Pinzi, V.; Bourhis, J.; Deutsch, E. Mechanisms of disease: Signaling of the insulin-like growth factor 1 receptor pathway—Therapeutic perspectives in cancer. Nat. Clin. Pract. Oncol. 2007, 4, 591–602.
[83]
Werner, H.; Le Roith, D. The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Crit. Rev. Oncog. 1997, 8, 71–92, doi:10.1615/CritRevOncog.v8.i1.40.
[84]
Turner, B.C.; Haffty, B.G.; Narayanan, L.; Yuan, J.; Havre, P.A.; Gumbs, A.A.; Kaplan, L.; Burgaud, J.L.; Carter, D.; Baserga, R.; et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 1997, 57, 3079–3083.
[85]
Macaulay, V.M.; Salisbury, A.J.; Bohula, E.A.; Playford, M.P.; Smorodinsky, N.I.; Shiloh, Y. Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase. Oncogene 2001, 20, 4029–4040, doi:10.1038/sj.onc.1204565.
[86]
Peretz, S.; Jensen, R.; Baserga, R.; Glazer, P.M. ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response. Proc. Natl. Acad. Sci. USA 2001, 98, 1676–1681, doi:10.1073/pnas.98.4.1676.
[87]
Rotman, G.; Shiloh, Y. ATM: A mediator of multiple responses to genotoxic stress. Oncogene 1999, 18, 6135–6144, doi:10.1038/sj.onc.1203124.
[88]
Trojanek, J.; Ho, T.; del Valle, L.; Nowicki, M.; Wang, J.Y.; Lassak, A.; Peruzzi, F.; Khalili, K.; Skorski, T.; Reiss, K. Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination. Mol. Cell Biol. 2003, 23, 7510–7524, doi:10.1128/MCB.23.21.7510-7524.2003.
Riesterer, O.; Yang, Q.; Raju, U.; Torres, M.; Molkentine, D.; Patel, N.; Valdecanas, D.; Milas, L.; Ang, K.K. Combination of anti-IGF-1R antibody A12 and ionizing radiation in upper respiratory tract cancers. Int. J. Radiat. Oncol. Biol. Phys. 2011, 79, 1179–1187, doi:10.1016/j.ijrobp.2010.10.003.
[91]
Laird, A.D.; Vajkoczy, P.; Shawver, L.K.; Thurnher, A.; Liang, C.; Mohammadi, M.; Schlessinger, J.; Ullrich, A.; Hubbard, S.R.; Blake, R.A.; et al. Cherrington SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 2000, 60, 4152–4160.
[92]
Griffin, R.J.; Williams, B.W.; Wild, R.; Cherrington, J.M.; Park, H.; Song, C.W. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res. 2002, 62, 1702–1706.
[93]
Ning, S.; Laird, D.; Cherrington, J.M.; Knox, S.J. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat. Res. 2002, 157, 45–51, doi:10.1667/0033-7587(2002)157[0045:TAASAS]2.0.CO;2.
[94]
Abdollahi, A.; Lipson, K.E.; Han, X.; Krempien, R.; Trinh, T.; Weber, K.J.; Hahnfeldt, P.; Hlatky, L.; Debus, J.; Howlett, A.R.; et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res. 2003, 63, 3755–3763.
[95]
Fong, T.A.; Shawver, L.K.; Sun, L.; Tang, C.; App, H.; Powell, T.J.; Kim, Y.H.; Schreck, R.; Wang, X.; Risau, W.; et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999, 59, 99–106.
[96]
Mendel, D.B.; Laird, A.D.; Smolich, B.D.; Blake, R.A.; Liang, C.; Hannah, A.L.; Shaheen, R.M.; Ellis, L.M.; Weitman, S.; Shawver, L.K.; et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des. 2000, 15, 29–41.
De Bacco, F.; Luraghi, P.; Medico, E.; Reato, G.; Girolami, F.; Perera, T.; Gabriele, P.; Comoglio, P.M.; Boccaccio, C. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J. Natl. Cancer Inst. 2011, 103, 645–661, doi:10.1093/jnci/djr093.
[99]
Medova, M.; Aebersold, D.M.; Blank-Liss, W.; Streit, B.; Medo, M.; Aebi, S.; Zimmer, Y. MET inhibition results in DNA breaks and synergistically sensitizes tumor cells to DNA-damaging agents potentially by breaching a damage-induced checkpoint arrest. Genes Cancer 2010, 1, 1053–1062, doi:10.1177/1947601910388030.
[100]
Ganapathipillai, S.S.; Medova, M.; Aebersold, D.M.; Manley, P.W.; Berthou, S.; Streit, B.; Blank-Liss, W.; Greiner, R.H.; Rothen-Rutishauser, B.; Zimmer, Y. Coupling of mutated Met variants to DNA repair via Abl and Rad51. Cancer Res. 2008, 68, 5769–5777, doi:10.1158/0008-5472.CAN-08-1269.
[101]
Medova, M.; Aebersold, D.M.; Zimmer, Y. MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks. Int. J. Cancer 2012, 130, 728–734, doi:10.1002/ijc.26058.
Fan, S.; Ma, Y.X.; Wang, J.A.; Yuan, R.Q.; Meng, Q.; Cao, Y.; Laterra, J.J.; Goldberg, I.D.; Rosen, E.M. The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3' kinase. Oncogene 2000, 19, 2212–2223, doi:10.1038/sj.onc.1203566.
[105]
Fan, S.; Ma, Y.X.; Gao, M.; Yuan, R.Q.; Meng, Q.; Goldberg, I.D.; Rosen, E.M. The multisubstrate adapter Gab1 regulates hepatocyte growth factor (scatter factor)-c-Met signaling for cell survival and DNA repair. Mol. Cell Biol. 2001, 21, 4968–4984, doi:10.1128/MCB.21.15.4968-4984.2001.
[106]
Maroun, C.R.; Moscatello, D.K.; Naujokas, M.A.; Holgado-Madruga, M.; Wong, A.J.; Park, M. A conserved inositol phospholipid binding site within the pleckstrin homology domain of the Gab1 docking protein is required for epithelial morphogenesis. J. Biol. Chem. 1999, 274, 31719–31726, doi:10.1074/jbc.274.44.31719.
[107]
Yuan, R.; Fan, S.; Achary, M.; Stewart, D.M.; Goldberg, I.D.; Rosen, E.M. Altered gene expression pattern in cultured human breast cancer cells treated with hepatocyte growth factor/scatter factor in the setting of DNA damage. Cancer Res. 2001, 61, 8022–8031.
[108]
Sheng-Hua, C.; Yan-Bin, M.; Zhi-An, Z.; Hong, Z.; Dong-Fu, F.; Zhi-Qiang, L.; Xian-Hou, Y. Radiation-enhanced hepatocyte growth factor secretion in malignant glioma cell lines. Surg. Neurol. 2007, 68, 610–613, doi:10.1016/j.surneu.2006.12.050.
[109]
Qian, L.W.; Mizumoto, K.; Inadome, N.; Nagai, E.; Sato, N.; Matsumoto, K.; Nakamura, T.; Tanaka, M. Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells. Int. J. Cancer 2003, 104, 542–549, doi:10.1002/ijc.10997.
[110]
Goetsch, L.; Caussanel, V.; Corvaia, N. Biological significance and targeting of c-Met tyrosine kinase receptor in cancer. Front. Biosci. (Landmark Ed.) 2013, 18, 454–473, doi:10.2741/4114.
Aebersold, D.M.; Kollar, A.; Beer, K.T.; Laissue, J.; Greiner, R.H.; Djonov, V. Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation. Int. J. Cancer 2001, 96, 41–54, doi:10.1002/1097-0215(20010220)96:1<41::AID-IJC5>3.0.CO;2-F.
[113]
Kim, Y.J.; Go, H.; Wu, H.G.; Jeon, Y.K.; Park, S.W.; Lee, S.H. Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy. Head Neck 2011, 33, 1458–1466, doi:10.1002/hed.21611.
[114]
Gao, J.; Inagaki, Y.; Song, P.; Qu, X.; Kokudo, N.; Tang, W. Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma. Pharmacol. Res. 2012, 65, 23–30, doi:10.1016/j.phrs.2011.11.011.
[115]
Raghav, K.P.; Wang, W.; Liu, S.; Chavez-MacGregor, M.; Meng, X.; Hortobagyi, G.N.; Mills, G.B.; Meric-Bernstam, F.; Blumenschein, G.R., Jr.; Gonzalez-Angulo, A.M. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin. Cancer Res. 2012, 18, 2269–2277, doi:10.1158/1078-0432.CCR-11-2830.
[116]
Kim, C.H.; Koh, Y.W.; Han, J.H.; Kim, J.W.; Lee, J.S.; Baek, S.J.; Hwang, H.S.; Choi, E.C. c-Met expression as an indicator of survival outcome in patients with oral tongue carcinoma. Head Neck 2010, 32, 1655–1664, doi:10.1002/hed.21383.
[117]
Di Renzo, M.F.; Olivero, M.; Martone, T.; Maffe, A.; Maggiora, P.; Stefani, A.D.; Valente, G.; Giordano, S.; Cortesina, G.; Comoglio, P.M. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000, 19, 1547–1555, doi:10.1038/sj.onc.1203455.
[118]
Aebersold, D.M.; Landt, O.; Berthou, S.; Gruber, G.; Beer, K.T.; Greiner, R.H.; Zimmer, Y. Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx. Oncogene 2003, 22, 8519–8523, doi:10.1038/sj.onc.1206968.
[119]
Sattler, M.; Reddy, M.M.; Hasina, R.; Gangadhar, T.; Salgia, R. The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther. Adv. Med. Oncol. 2011, 3, 171–184, doi:10.1177/1758834011408636.
[120]
Eder, J.P.; vande Woude, G.F.; Boerner, S.A.; LoRusso, P.M. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin. Cancer Res. 2009, 15, 2207–2214, doi:10.1158/1078-0432.CCR-08-1306.
[121]
Lal, B.; Xia, S.; Abounader, R.; Laterra, J. Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin. Cancer Res. 2005, 11, 4479–4486, doi:10.1158/1078-0432.CCR-05-0166.
[122]
Chu, S.H.; Zhu, Z.A.; Yuan, X.H.; Li, Z.Q.; Jiang, P.C. In vitro and in vivo potentiating the cytotoxic effect of radiation on human U251 gliomas by the c-Met antisense oligodeoxynucleotides. J. Neurooncol. 2006, 80, 143–149, doi:10.1007/s11060-006-9174-5.
[123]
Yu, H.; Li, X.; Sun, S.; Gao, X.; Zhou, D. c-Met inhibitor SU11274 enhances the response of the prostate cancer cell line DU145 to ionizing radiation. Biochem. Biophys. Res. Commun. 2012, 427, 659–665, doi:10.1016/j.bbrc.2012.09.117.
[124]
Bhardwaj, V.; Zhan, Y.; Cortez, M.A.; Ang, K.K.; Molkentine, D.; Munshi, A.; Raju, U.; Komaki, R.; Heymach, J.V.; Welsh, J. C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression. J. Thorac. Oncol. 2012, 7, 1211–1217, doi:10.1097/JTO.0b013e318257cc89.
[125]
Lin, C.I.; Whang, E.E.; Donner, D.B.; Du, J.; Lorch, J.; He, F.; Jiang, X.; Price, B.D.; Moore, F.D., Jr.; Ruan, D.T. Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer. Mol. Cancer Res. 2010, 8, 1217–1226, doi:10.1158/1541-7786.MCR-10-0162.
[126]
Buchanan, I.M.; Scott, T.; Tandle, A.T.; Burgan, W.E.; Burgess, T.L.; Tofilon, P.J.; Camphausen, K. Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102. J. Cell. Mol. Med. 2011, 15, 1999–2006, doi:10.1111/j.1582-4934.2010.01122.x.
[127]
Khanna, K.K.; Jackson, S.P. DNA double-strand breaks: Signaling, repair and the cancer connection. Nat. Genet. 2001, 27, 247–254, doi:10.1038/85798.
[128]
Chen, G.; Yuan, S.S.; Liu, W.; Xu, Y.; Trujillo, K.; Song, B.; Cong, F.; Goff, S.P.; Wu, Y.; Arlinghaus, R.; et al. Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J. Biol. Chem. 1999, 274, 12748–12752, doi:10.1074/jbc.274.18.12748.
[129]
Takizawa, Y.; Kinebuchi, T.; Kagawa, W.; Yokoyama, S.; Shibata, T.; Kurumizaka, H. Mutational analyses of the human Rad51-Tyr315 residue, a site for phosphorylation in leukaemia cells. Genes Cells 2004, 9, 781–790, doi:10.1111/j.1365-2443.2004.00772.x.
Jain, R.K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005, 307, 58–62, doi:10.1126/science.1104819.
[135]
Harris, A.L. Hypoxia—A key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2, 38–47, doi:10.1038/nrc704.
[136]
Brizel, D.M.; Sibley, G.S.; Prosnitz, L.R.; Scher, R.L.; Dewhirst, M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 1997, 38, 285–289, doi:10.1016/S0360-3016(97)00101-6.
[137]
Hockel, M.; Schlenger, K.; Aral, B.; Mitze, M.; Schaffer, U.; Vaupel, P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996, 56, 4509–4515.
[138]
Kaanders, J.H.; Wijffels, K.I.; Marres, H.A.; Ljungkvist, A.S.; Pop, L.A.; van den Hoogen, F.J.; de Wilde, P.C.; Bussink, J.; Raleigh, J.A.; van der Kogel, A.J. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res. 2002, 62, 7066–7074.
[139]
Nordsmark, M.; Bentzen, S.M.; Rudat, V.; Brizel, D.; Lartigau, E.; Stadler, P.; Becker, A.; Adam, M.; Molls, M.; Dunst, J.; et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother. Oncol. 2005, 77, 18–24, doi:10.1016/j.radonc.2005.06.038.
[140]
Vaupel, P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin. Radiat. Oncol. 2004, 14, 198–206, doi:10.1016/j.semradonc.2004.04.008.
[141]
Kim, J.W.; Tchernyshyov, I.; Semenza, G.L.; Dang, C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006, 3, 177–185, doi:10.1016/j.cmet.2006.02.002.
[142]
Bindra, R.S.; Schaffer, P.J.; Meng, A.; Woo, J.; Maseide, K.; Roth, M.E.; Lizardi, P.; Hedley, D.W.; Bristow, R.G.; Glazer, P.M. Alterations in DNA repair gene expression under hypoxia: Elucidating the mechanisms of hypoxia-induced genetic instability. Ann. N. Y. Acad. Sci. 2005, 1059, 184–195.
[143]
Tang, N.; Wang, L.; Esko, J.; Giordano, F.J.; Huang, Y.; Gerber, H.P.; Ferrara, N.; Johnson, R.S. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004, 6, 485–495, doi:10.1016/j.ccr.2004.09.026.
Tredan, O.; Galmarini, C.M.; Patel, K.; Tannock, I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99, 1441–1454, doi:10.1093/jnci/djm135.
[146]
Hockel, M.; Vaupel, P. Biological consequences of tumor hypoxia. Semin. Oncol. 2001, 28, 36–41, doi:10.1016/S0093-7754(01)90211-8.
[147]
Hockel, M.; Vaupel, P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 2001, 93, 266–276, doi:10.1093/jnci/93.4.266.
[148]
Nordsmark, M.; Overgaard, M.; Overgaard, J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 1996, 41, 31–39.
[149]
Gatenby, R.A.; Kessler, H.B.; Rosenblum, J.S.; Coia, L.R.; Moldofsky, P.J.; Hartz, W.H.; Broder, G.J. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 1988, 14, 831–838, doi:10.1016/0360-3016(88)90002-8.
[150]
Brizel, D.M.; Dodge, R.K.; Clough, R.W.; Dewhirst, M.W. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother. Oncol. 1999, 53, 113–117, doi:10.1016/S0167-8140(99)00102-4.
[151]
Aebersold, D.M.; Burri, P.; Beer, K.T.; Laissue, J.; Djonov, V.; Greiner, R.H.; Semenza, G.L. Expression of hypoxia-inducible factor-1alpha: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001, 61, 2911–2916.
[152]
Bachtiary, B.; Schindl, M.; Potter, R.; Dreier, B.; Knocke, T.H.; Hainfellner, J.A.; Horvat, R.; Birner, P. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin. Cancer Res. 2003, 9, 2234–2240.
[153]
Trusolino, L.; Bertotti, A.; Comoglio, P.M. MET signalling: Principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 2010, 11, 834–848, doi:10.1038/nrm3012.
[154]
Hara, S.; Nakashiro, K.; Klosek, S.K.; Ishikawa, T.; Shintani, S.; Hamakawa, H. Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells. Oral Oncol. 2006, 42, 593–598, doi:10.1016/j.oraloncology.2005.10.016.
[155]
Chen, H.H.; Su, W.C.; Lin, P.W.; Guo, H.R.; Lee, W.Y. Hypoxia-inducible factor-1alpha correlates with MET and metastasis in node-negative breast cancer. Breast Cancer Res. Treat. 2007, 103, 167–175.
[156]
Scarpino, S.; Cancellario d'Alena, F.; Di Napoli, A.; Pasquini, A.; Marzullo, A.; Ruco, L.P. Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. J. Pathol. 2004, 202, 352–358, doi:10.1002/path.1522.
[157]
Ide, T.; Kitajima, Y.; Miyoshi, A.; Ohtsuka, T.; Mitsuno, M.; Ohtaka, K.; Koga, Y.; Miyazaki, K. Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway. Int. J. Cancer 2006, 119, 2750–2759, doi:10.1002/ijc.22178.
